Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis

[1]  E. Roilides,et al.  Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. , 2014, The Lancet. Oncology.

[2]  T. Hohl,et al.  The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. Seyedmousavi,et al.  Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis , 2013, Expert review of anti-infective therapy.

[4]  N. Hatipoğlu,et al.  Combination antifungal therapy for invasive fungal infections in children and adults , 2013, Expert review of anti-infective therapy.

[5]  H. Koo,et al.  Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients , 2013, Pediatric blood & cancer.

[6]  A. Ayadi,et al.  Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis. , 2012, Pathologie-biologie.

[7]  Kieren A Marr,et al.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. , 2012, The Journal of infection.

[8]  R. Takimoto,et al.  Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.

[9]  S. Han,et al.  Epidemiology and Clinical outcomes of Invasive Pulmonary Aspergillosis: A Nationwide Multicenter Study in Korea , 2012 .

[10]  A. Borkhardt,et al.  Invasive Aspergillosis in Pediatric Oncology Patients: A Rare Event With Poor Prognosis – Case Analysis to Plan Better Targeted Prophylactic or Therapeutic Measurement , 2012, Klinische Pädiatrie.

[11]  Yoo-Jin Kim,et al.  Prognosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases in Korea , 2012, Tuberculosis and respiratory diseases.

[12]  J. Latgé,et al.  Prospective Evaluation of Clinical and Biological Markers To Predict the Outcome of Invasive Pulmonary Aspergillosis in Hematological Patients , 2011, Journal of Clinical Microbiology.

[13]  S. Park,et al.  Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients , 2011, Mycoses.

[14]  I. Yaniv,et al.  Invasive fungal infections in pediatric oncology , 2011, Pediatric blood & cancer.

[15]  S. Kim,et al.  Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea , 2011, The Korean journal of internal medicine.

[16]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  S. Koo,et al.  Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis , 2010, Journal of Clinical Microbiology.

[18]  M. Cuenca‐Estrella,et al.  Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade: A Retrospective Single Centre Study , 2009, Journal of pediatric hematology/oncology.

[19]  A. Kalkancı,et al.  Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis , 2009, Pediatric blood & cancer.

[20]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  G. Verhoef,et al.  Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients , 2009, Cancer.

[22]  H. Einsele,et al.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2008, International journal of hematology.

[23]  Philippe Lutun,et al.  Factors associated with overall and attributable mortality in invasive aspergillosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Graybill,et al.  Assessment of Aspergillus fumigatus Burden in Pulmonary Tissue of Guinea Pigs by Quantitative PCR, Galactomannan Enzyme Immunoassay, and Quantitative Culture , 2008, Antimicrobial Agents and Chemotherapy.

[27]  W. Steinbach,et al.  Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases , 2008, Pediatrics.

[28]  B. Barlogie,et al.  Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  S. de Botton,et al.  Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies , 2007, Cancer.

[31]  B. Barlogie,et al.  Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis , 2007, Cancer.

[32]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Raoul Herbrecht,et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  S. Cesaro,et al.  Combination antifungal therapy for invasive aspergillosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  H. Verbrugh,et al.  Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. , 2003, The Journal of antimicrobial chemotherapy.

[37]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[38]  B. François,et al.  Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease , 2002 .

[39]  F. Derouin,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  S. Piscitelli,et al.  Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia , 2001, Antimicrobial Agents and Chemotherapy.

[41]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Latgé,et al.  Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. , 1996, The Pediatric infectious disease journal.

[43]  E. Fishman,et al.  CT of invasive pulmonary aspergillosis. , 1988, AJR. American journal of roentgenology.